BET Inhibition Suppresses S100A8 and S100A9 Expression in Acute Myeloid Leukemia Cells and Synergises with Daunorubicin in Causing Cell Death | Zendy

Helen Stewart | Zendy; Sabah F. Chaudry | Zendy; Asante Crichlow | Zendy; Freya Luling Feilding | Zendy; Timothy Chevassut | Zendy

Open Access

BET Inhibition Suppresses S100A8 and S100A9 Expression in Acute Myeloid Leukemia Cells and Synergises with Daunorubicin in Causing Cell Death

Author(s) -

Helen Stewart,

Sabah F. Chaudry,

Asante Crichlow,

Freya Luling Feilding,

Timothy Chevassut

Publication year - 2018

Publication title -

bone marrow research

Language(s) - English

Resource type - Journals

eISSN - 2090-2999

pISSN - 2090-3006

DOI - 10.1155/2018/5742954

Subject(s) - daunorubicin , medicine , s100a8 , s100a9 , myeloid leukemia , apoptosis , myeloid , programmed cell death , cancer research , bromodomain , leukemia , immunology , biology , inflammation , acetylation , biochemistry , gene

S100A8 and S100A9 are both members of the S100 family and have been shown to play roles in myeloid differentiation, autophagy, apoptosis, and chemotherapy resistance. In this study we demonstrate that the BET-bromodomain inhibitor JQ1 causes rapid suppression of S100A8 and S100A9 mRNA and protein in a reversible manner. In addition, we show that JQ1 synergises with daunorubicin in causing AML cell death. Daunorubicin alone causes a dose- and time-dependent increase in S100A8 and S100A9 protein levels in AML cell lines which is overcome by cotreatment with JQ1. This suggests that JQ1 synergises with daunorubicin in causing apoptosis via suppression of S100A8 and S100A9 levels.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research